NASDAQ:CTNM Contineum Therapeutics (CTNM) Stock Price, News & Analysis $11.49 -0.85 (-6.89%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$11.52 +0.03 (+0.22%) As of 06/5/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Contineum Therapeutics Stock (NASDAQ:CTNM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Contineum Therapeutics alerts:Sign Up Key Stats Today's Range$11.46▼$12.4750-Day Range$11.49▼$14.9452-Week Range$3.57▼$16.33Volume285,368 shsAverage Volume161,956 shsMarket Capitalization$429.61 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingModerate Buy Company Overview Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California. Read More Contineum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreCTNM MarketRank™: Contineum Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 576th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingContineum Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialContineum Therapeutics has a consensus price target of $20.00, representing about 74.1% upside from its current price of $11.49.Amount of Analyst CoverageContineum Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Contineum Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Contineum Therapeutics are expected to decrease in the coming year, from ($1.68) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Contineum Therapeutics is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Contineum Therapeutics is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContineum Therapeutics has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Contineum Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.27% of the float of Contineum Therapeutics has been sold short.Short Interest Ratio / Days to CoverContineum Therapeutics has a short interest ratio ("days to cover") of 6.74.Change versus previous monthShort interest in Contineum Therapeutics has recently decreased by 11.70%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContineum Therapeutics does not currently pay a dividend.Dividend GrowthContineum Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Contineum Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for CTNM on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Contineum Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Contineum Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.30% of the stock of Contineum Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsContineum Therapeutics has minimal institutional ownership at this time.Read more about Contineum Therapeutics' insider trading history. Receive CTNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTNM Stock News HeadlinesContineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Recommendation of "Moderate Buy" by AnalystsJune 5 at 2:57 AM | americanbankingnews.comContineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare ConferenceJune 1, 2026 | businesswire.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 6 at 1:00 AM | Porter & Company (Ad)Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare ConferenceMay 12, 2026 | businesswire.comContineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International ConferenceMay 11, 2026 | finance.yahoo.comContineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development MilestonesMay 6, 2026 | finance.yahoo.comContineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety BarMay 2, 2026 | msn.comContineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | businesswire.comSee More Headlines CTNM Stock Analysis - Frequently Asked Questions How have CTNM shares performed this year? Contineum Therapeutics' stock was trading at $11.43 at the start of the year. Since then, CTNM stock has increased by 0.5% and is now trading at $11.49. How were Contineum Therapeutics' earnings last quarter? Contineum Therapeutics, Inc. (NASDAQ:CTNM) posted its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.16. When did Contineum Therapeutics IPO? Contineum Therapeutics (CTNM) raised $117 million in an IPO on Friday, April 5th 2024. The company issued 6,875,000 shares at $16.00-$18.00 per share. Who are Contineum Therapeutics' major shareholders? Top institutional shareholders of Contineum Therapeutics include Janus Henderson Group PLC (7.31%), Perceptive Advisors LLC (3.36%), ADAR1 Capital Management LLC (0.74%) and Eversept Partners LP (0.39%). How do I buy shares of Contineum Therapeutics? Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Contineum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Contineum Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/05/2026Today6/06/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 CTNM's financial health is in the Green zone, according to TradeSmith. CTNM has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTNM Previous SymbolNASDAQ:CTNM CIK1855175 Webwww.contineum-tx.com Phone(858) 333-5280FaxN/AEmployees31Year Founded2017Price Target and Rating Average Price Target for Contineum Therapeutics$20.00 High Price Target$22.00 Low Price Target$16.00 Potential Upside/Downside+74.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-27.09% Return on Assets-25.64% Debt Debt-to-Equity RatioN/A Current Ratio38.00 Quick Ratio38.00 Sales & Book Value Annual Sales$50 million Price / Sales8.59 Cash FlowN/A Price / Cash FlowN/A Book Value$6.99 per share Price / Book1.64Miscellaneous Outstanding Shares37,390,000Free Float33,161,000Market Cap$429.61 million OptionableN/A Beta0.89 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:CTNM) was last updated on 6/6/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredBUY THIS: Claim a backdoor stake in SpaceX before June 12SpaceX isn't public yet, but one trade available in a standard brokerage account could give you pre-IPO exposu...Chaikin Analytics | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredHow to get into the SpaceX IPO before June 12Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
